Vir Biotechnology Inc. [NASDAQ: VIR] traded at a low on 07/02/21, posting a -4.36 loss after which it closed the day’ session at $41.63. The company report on June 25, 2021 that Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021.
– Results demonstrate positive safety profiles and a reduction in HBsAg for two novel HBV therapies administrated as monotherapy or in combination with other agents –.
– Management to host conference call , Friday, June 25, 2021, at 11:00 a.m. ET –.
The results of the trading session contributed to over 762693 shares changing hands. Over the past one week, the price volatility of Vir Biotechnology Inc. stands at 5.75% while the volatility over the past one month is 6.08%.
The market cap for VIR stock reached $5.66 billion, with 127.74 million shares outstanding and 113.06 million shares in the current float. Compared to the average trading volume of 719.19K shares, VIR reached a trading volume of 762693 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Vir Biotechnology Inc. [VIR]?
Robert W. Baird have made an estimate for Vir Biotechnology Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 04, 2021. The new note on the price target was released on January 27, 2021, representing the official price target for Vir Biotechnology Inc. stock. Previously, the target price had yet another raise from $100 to $125, while H.C. Wainwright kept a Buy rating on VIR stock.
The Average True Range (ATR) for Vir Biotechnology Inc. is set at 2.83, with the Price to Sales ratio for VIR stock in the period of the last 12 months amounting to 77.97. The Price to Book ratio for the last quarter was 8.16, with the Price to Cash per share for the same quarter was set at 5.39.
How has VIR stock performed recently?
Vir Biotechnology Inc. [VIR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.53. With this latest performance, VIR shares dropped by -9.48% in over the last four-week period, additionally plugging by 55.45% over the last 6 months – not to mention a rise of 3.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VIR stock in for the last two-week period is set at 40.63, with the RSI for the last a single of trading hit 35.61, and the three-weeks RSI is set at 43.37 for Vir Biotechnology Inc. [VIR]. The present Moving Average for the last 50 days of trading for this stock 45.05, while it was recorded at 45.17 for the last single week of trading, and 43.28 for the last 200 days.
Vir Biotechnology Inc. [VIR]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Vir Biotechnology Inc. [VIR] shares currently have an operating margin of -387.79. Vir Biotechnology Inc.’s Net Margin is presently recorded at -391.09.
Return on Total Capital for VIR is now -48.83, given the latest momentum, and Return on Invested Capital for the company is -49.41. Return on Equity for this stock declined to -52.36, with Return on Assets sitting at -41.75. When it comes to the capital structure of this company, Vir Biotechnology Inc. [VIR] has a Total Debt to Total Equity ratio set at 9.92. Additionally, VIR Total Debt to Total Capital is recorded at 9.03, with Total Debt to Total Assets ending up at 7.74. Long-Term Debt to Equity for the company is recorded at 9.38, with the Long-Term Debt to Total Capital now at 8.54.
Reflecting on the efficiency of the workforce at the company, Vir Biotechnology Inc. [VIR] managed to generate an average of -$913,349 per employee.Vir Biotechnology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.80 and a Current Ratio set at 2.80.
Earnings analysis for Vir Biotechnology Inc. [VIR]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VIR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Vir Biotechnology Inc. go to 7.00%.
Insider trade positions for Vir Biotechnology Inc. [VIR]
There are presently around $3,151 million, or 79.20% of VIR stock, in the hands of institutional investors. The top three institutional holders of VIR stocks are: SB INVESTMENT ADVISERS (UK) LTD with ownership of 22,616,666, which is approximately 0% of the company’s market cap and around 5.30% of the total institutional ownership; CAPITAL INTERNATIONAL INVESTORS, holding 11,822,763 shares of the stock with an approximate value of $492.18 million in VIR stocks shares; and VANGUARD GROUP INC, currently with $247.2 million in VIR stock with ownership of nearly 1.158% of the company’s market capitalization.
Positions in Vir Biotechnology Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 76 institutional holders increased their position in Vir Biotechnology Inc. [NASDAQ:VIR] by around 4,420,090 shares. Additionally, 88 investors decreased positions by around 7,098,087 shares, while 13 investors held positions by with 64,163,546 shares. The mentioned changes placed institutional holdings at 75,681,723 shares, according to the latest SEC report filing. VIR stock had 39 new institutional investments in for a total of 1,706,052 shares, while 25 institutional investors sold positions of 2,775,876 shares during the same period.